Cargando…

Natural History of Leigh Syndrome: A Study of Disease Burden and Progression

OBJECTIVE: This observational cohort study aims to quantify disease burden over time, establish disease progression rates, and identify factors that may determine the disease course of Leigh syndrome. METHODS: Seventy‐two Leigh syndrome children who completed the Newcastle Paediatric Mitochondrial D...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Albert Z., Ng, Yi Shiau, Blain, Alasdair, Jiminez‐Moreno, Cecilia, Alston, Charlotte L., Nesbitt, Victoria, Simmons, Louise, Santra, Saikat, Wassmer, Evangeline, Blakely, Emma L., Turnbull, Doug M., Taylor, Robert W., Gorman, Gráinne S., McFarland, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534328/
https://www.ncbi.nlm.nih.gov/pubmed/34716721
http://dx.doi.org/10.1002/ana.26260
_version_ 1784802518215163904
author Lim, Albert Z.
Ng, Yi Shiau
Blain, Alasdair
Jiminez‐Moreno, Cecilia
Alston, Charlotte L.
Nesbitt, Victoria
Simmons, Louise
Santra, Saikat
Wassmer, Evangeline
Blakely, Emma L.
Turnbull, Doug M.
Taylor, Robert W.
Gorman, Gráinne S.
McFarland, Robert
author_facet Lim, Albert Z.
Ng, Yi Shiau
Blain, Alasdair
Jiminez‐Moreno, Cecilia
Alston, Charlotte L.
Nesbitt, Victoria
Simmons, Louise
Santra, Saikat
Wassmer, Evangeline
Blakely, Emma L.
Turnbull, Doug M.
Taylor, Robert W.
Gorman, Gráinne S.
McFarland, Robert
author_sort Lim, Albert Z.
collection PubMed
description OBJECTIVE: This observational cohort study aims to quantify disease burden over time, establish disease progression rates, and identify factors that may determine the disease course of Leigh syndrome. METHODS: Seventy‐two Leigh syndrome children who completed the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) at baseline at 3.7 years (interquartile range [IQR] = 2.0–7.6) and follow‐up assessments at 7.5 years (IQR = 3.7–11.0) in clinics were enrolled. Eighty‐two percent of this cohort had a confirmed genetic diagnosis, with pathogenic variants in the MT‐ATP6 and SURF1 genes being the most common cause. The total NPMDS scores denoted mild (0–14), moderate (15–25), and severe (>25) disease burden. Detailed clinical, neuroradiological, and molecular genetic findings were also analyzed. RESULTS: The median total NPMDS scores rose significantly (Z = −6.9, p < 0.001), and the percentage of children with severe disease burden doubled (22% → 42%) over 2.6 years of follow‐up. Poor function (especially mobility, self‐care, communication, feeding, and education) and extrapyramidal features contributed significantly to the disease burden (τ (b) ≈ 0.45–0.68, p < 0.001). These children also deteriorated to wheelchair dependence (31% → 57%), exclusive enteral feeding (22% → 46%), and one‐to‐one assistance for self‐care (25% → 43%) during the study period. Twelve children (17%) died after their last NPMDS scores were recorded. These children had higher follow‐up NPMDS scores (disease burden; p < 0.001) and steeper increase in NPMDS score per annum (disease progression; p < 0.001). Other predictors of poor outcomes include SURF1 gene variants (p < 0.001) and bilateral caudate changes on neuroimaging (p < 0.01). INTERPRETATION: This study has objectively defined the disease burden and progression of Leigh syndrome. Our analysis has also uncovered potential influences on the trajectory of this neurodegenerative condition. ANN NEUROL 2022;91:117–130
format Online
Article
Text
id pubmed-9534328
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-95343282022-10-11 Natural History of Leigh Syndrome: A Study of Disease Burden and Progression Lim, Albert Z. Ng, Yi Shiau Blain, Alasdair Jiminez‐Moreno, Cecilia Alston, Charlotte L. Nesbitt, Victoria Simmons, Louise Santra, Saikat Wassmer, Evangeline Blakely, Emma L. Turnbull, Doug M. Taylor, Robert W. Gorman, Gráinne S. McFarland, Robert Ann Neurol Research Articles OBJECTIVE: This observational cohort study aims to quantify disease burden over time, establish disease progression rates, and identify factors that may determine the disease course of Leigh syndrome. METHODS: Seventy‐two Leigh syndrome children who completed the Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) at baseline at 3.7 years (interquartile range [IQR] = 2.0–7.6) and follow‐up assessments at 7.5 years (IQR = 3.7–11.0) in clinics were enrolled. Eighty‐two percent of this cohort had a confirmed genetic diagnosis, with pathogenic variants in the MT‐ATP6 and SURF1 genes being the most common cause. The total NPMDS scores denoted mild (0–14), moderate (15–25), and severe (>25) disease burden. Detailed clinical, neuroradiological, and molecular genetic findings were also analyzed. RESULTS: The median total NPMDS scores rose significantly (Z = −6.9, p < 0.001), and the percentage of children with severe disease burden doubled (22% → 42%) over 2.6 years of follow‐up. Poor function (especially mobility, self‐care, communication, feeding, and education) and extrapyramidal features contributed significantly to the disease burden (τ (b) ≈ 0.45–0.68, p < 0.001). These children also deteriorated to wheelchair dependence (31% → 57%), exclusive enteral feeding (22% → 46%), and one‐to‐one assistance for self‐care (25% → 43%) during the study period. Twelve children (17%) died after their last NPMDS scores were recorded. These children had higher follow‐up NPMDS scores (disease burden; p < 0.001) and steeper increase in NPMDS score per annum (disease progression; p < 0.001). Other predictors of poor outcomes include SURF1 gene variants (p < 0.001) and bilateral caudate changes on neuroimaging (p < 0.01). INTERPRETATION: This study has objectively defined the disease burden and progression of Leigh syndrome. Our analysis has also uncovered potential influences on the trajectory of this neurodegenerative condition. ANN NEUROL 2022;91:117–130 John Wiley & Sons, Inc. 2021-11-12 2022-01 /pmc/articles/PMC9534328/ /pubmed/34716721 http://dx.doi.org/10.1002/ana.26260 Text en © 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Lim, Albert Z.
Ng, Yi Shiau
Blain, Alasdair
Jiminez‐Moreno, Cecilia
Alston, Charlotte L.
Nesbitt, Victoria
Simmons, Louise
Santra, Saikat
Wassmer, Evangeline
Blakely, Emma L.
Turnbull, Doug M.
Taylor, Robert W.
Gorman, Gráinne S.
McFarland, Robert
Natural History of Leigh Syndrome: A Study of Disease Burden and Progression
title Natural History of Leigh Syndrome: A Study of Disease Burden and Progression
title_full Natural History of Leigh Syndrome: A Study of Disease Burden and Progression
title_fullStr Natural History of Leigh Syndrome: A Study of Disease Burden and Progression
title_full_unstemmed Natural History of Leigh Syndrome: A Study of Disease Burden and Progression
title_short Natural History of Leigh Syndrome: A Study of Disease Burden and Progression
title_sort natural history of leigh syndrome: a study of disease burden and progression
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534328/
https://www.ncbi.nlm.nih.gov/pubmed/34716721
http://dx.doi.org/10.1002/ana.26260
work_keys_str_mv AT limalbertz naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT ngyishiau naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT blainalasdair naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT jiminezmorenocecilia naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT alstoncharlottel naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT nesbittvictoria naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT simmonslouise naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT santrasaikat naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT wassmerevangeline naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT blakelyemmal naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT turnbulldougm naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT taylorrobertw naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT gormangrainnes naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression
AT mcfarlandrobert naturalhistoryofleighsyndromeastudyofdiseaseburdenandprogression